Taking into account the necessity of plasmin for the development of radiodermatitis, we propose a novel preventive therapy using clinically approved lysine analogs (such as TXA or ɛ-aminocaproid acid) to inhibit plasminogen activation and thereby prevent or reduce the development of radiodermatitis in cancer patients undergoing radiotherapy. Here, PLG is linked to cancer.